2022 ÇϹݱ⠴ٹ߰ñ¼öÁ¾ workshop&Àӻ󿬱¸¸ðÀÓ : 2022-11-19±³À°ÀÏÀÚ : 2022-11-19
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ
±³À°ÁÖÁ¦ :
2022 ÇϹݱ⠴ٹ߰ñ¼öÁ¾ workshop&Àӻ󿬱¸¸ðÀÓÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
kmmwp_office@naver.com ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 09:30~10:00 IMS 2022 Highlights_NDMM ¹Ú¼º¼ö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 10:00~10:30 IMS 2022 Highlights_RRMM (including ADC) º¯ÀÚ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 10:30~11:00 IMS 2022 Highlights_Cellular immunotherapy (BiTE, CAR-T) ±è´ë½Ä(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 11:10~11:30 Genetics based risk stratification ±è¹Ì¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 11:30~11:50 Functional high risk Á¶ÈñÁ¤(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 11:50~12:10 Ongoing Clinical trials in HRMM ¹Ú¿µÈÆ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 13:10~13:30 Current diagnosis and monitoring of smoldering MM Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 13:30~13:50 Early treatment for smoldering MM Á¶Àçö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 14:00~14:40 Àӻ󿬱¸ I (study during results analysis) ½ÅÈ£Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 14:50~15:50 Àӻ󿬱¸ II (current active protocol) ¹æ¼ö¹Ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-19 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI Ȧ 16:00~17:00 Àӻ󿬱¸ III (new protocol proposal) ±è¼ºÇö(µ¿¾ÆÀÇ´ë)